Heathers, J. (2021, October 23). The Real Scandal About Ivermectin. The Atlantic. https://www.theatlantic.com/science/archive/2021/10/ivermectin-research-problems/620473/

Smith, G. C. S., & Pell, J. P. (2003). Parachute use to prevent death and major trauma related to gravitational challenge: Systematic review of randomised controlled trials. BMJ : British Medical Journal, 327(7429), 1459–1461.

Agarwal, A., Rochwerg, B., Lamontagne, F., Siemieniuk, R. A., Agoritsas, T., Askie, L., Lytvyn, L., Leo, Y.-S., Macdonald, H., Zeng, L., Amin, W., Barragan, F. A., Bausch, F. J., Burhan, E., Calfee, C. S., Cecconi, M., Chanda, D., Dat, V. Q., Sutter, A. D., … Vandvik, P. O. (2020). A living WHO guideline on drugs for covid-19. BMJ, 370, m3379. https://doi.org/10.1136/bmj.m3379

the prasad, myocarditis up-player. (2022, January 18). No RCTs necessary to slay all you myocarditis downplayers https://t.co/tmGE6GwwJU [Tweet]. @VpwndF. https://twitter.com/VpwndF/status/1483514263750729733

Ortiz, J. R., & Neuzil, K. M. (2021). The value of vaccine programme impact monitoring during the COVID-19 pandemic. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(21)02322-9

Parsons, J. E., Newby, K. V., & French, D. P. (2018). Do interventions containing risk messages increase risk appraisal and the subsequent vaccination intentions and uptake? – A systematic review and meta‐analysis. British Journal of Health Psychology, 23(4), 1084–1106. https://doi.org/10.1111/bjhp.12340

Gobeil, P., Pillet, S., Séguin, A., Boulay, I., Mahmood, A., Vinh, D. C., Charland, N., Boutet, P., Roman, F., Most, R. V. D., Perez, M. de los A. C., Ward, B. J., & Landry, N. (2021). Interim Report of a Phase 2 Randomized Trial of a Plant-Produced Virus-Like Particle Vaccine for Covid-19 in Healthy Adults Aged 18-64 and Older Adults Aged 65 and Older. MedRxiv, 2021.05.14.21257248. https://doi.org/10.1101/2021.05.14.21257248

Jacobson Vann, J. C., Jacobson, R. M., Coyne‐Beasley, T., Asafu‐Adjei, J. K., & Szilagyi, P. G. (2018). Patient reminder and recall interventions to improve immunization rates. The Cochrane Database of Systematic Reviews, 2018(1). https://doi.org/10.1002/14651858.CD003941.pub3

Bar-Zeev, N., & Kochhar, S. (2020). Expecting the unexpected with COVID-19 vaccines. The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(20)30870-7

Epidemiology 101 for Journalists. (n.d.). Epidemiology, Biostatistics and Occupational Health. Retrieved 23 February 2021, from https://www.mcgill.ca/epi-biostat-occh/epidemiology-101-journalists

Helmus, Todd C., James V. Marrone, Marek N. Posard, and Danielle Schlang. ‘Russian Propaganda Hits Its Mark: Experimentally Testing the Impact of Russian Propaganda and Counter-Interventions’, 15 October 2020. https://www.rand.org/pubs/research_reports/RRA704-3.html.

Brewer, N. T., Hall, M. E., Malo, T. L., Gilkey, M. B., Quinn, B., & Lathren, C. (2017). Announcements Versus Conversations to Improve HPV Vaccination Coverage: A Randomized Trial. Pediatrics, 139(1). https://doi.org/10.1542/peds.2016-1764

Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., Bibi, S., Briner, C., Cicconi, P., Collins, A. M., Colin-Jones, R., Cutland, C. L., Darton, T. C., Dheda, K., Duncan, C. J. A., … Zuidewind, P. (2020). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(20)32661-1

Siemieniuk, R. A., Bartoszko, J. J., Ge, L., Zeraatkar, D., Izcovich, A., Kum, E., Pardo-Hernandez, H., Rochwerg, B., Lamontagne, F., Han, M. A., Liu, Q., Agarwal, A., Agoritsas, T., Chu, D. K., Couban, R., Darzi, A., Devji, T., Fang, B., Fang, C., … Brignardello-Petersen, R. (2020). Drug treatments for covid-19: Living systematic review and network meta-analysis. BMJ, 370. https://doi.org/10.1136/bmj.m2980

Gorey, C. (2020, June 29). RCSI team to start trial for promising Covid-19 therapy for severe infections. Silicon Republic. https://www.siliconrepublic.com/innovation/rcsi-trial-covid-19-therapy-alpha-1-antitrypsin

Dr Nisreen Alwan 🌻 on Twitter: “There’s no randomised trial evidence for social distancing, hand washing or even testing & contact tracing on #COVID19 so why is it being demanded for masks? I’m for it in all enclosed public spaces (if you can). We need to smile a tiny bit wider though so it shows from our eyes. https://t.co/3J3FToWeud” / Twitter. (n.d.). Twitter. Retrieved July 16, 2020, from https://twitter.com/Dr2NisreenAlwan/status/1281961332963770368

Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., Wu, S.-P., Wang, Z., Wu, X.-H., Xu, J.-J., Zhang, Z., Jia, S.-Y., Wang, B.-S., Hu, Y., Liu, J.-J., … Chen, W. (2020). Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(20)31605-6

Khan MS, Fonarow GC, Friede T, et al. Application of the Reverse Fragility Index to Statistically Nonsignificant Randomized Clinical Trial Results. JAMA Netw Open. 2020;3(8):e2012469. doi:10.1001/jamanetworkopen.2020.12469

Haushofer, J., & Metcalf, C. J. E. (2020). Which interventions work best in a pandemic? Science. https://doi.org/10.1126/science.abb6144

Jena, A. B., & Worsham, C. M. (2020, June 30). What Coronavirus Researchers Can Learn From Economists. The New York Times. https://www.nytimes.com/2020/06/30/upshot/coronavirus-economists-dexamethasone.html

The individual change in REE to a given change in dose varied radically. The dose change was only 50 mcg, which seemed to change TSH about half what they've calculated for 15% REE change. That is to say, it looks like a 50 mcg dose reduction will only raise TSH from 1.0 to 5.0, not to 10.0. This is my personal guesstimate, and will need to be properly calculated from other studies. My point is merely that 50 mcg will not cause the full 15% REE increase. Additionally, the response to 50 mcg may depend on initial TSH.

It looks like TSH changes that remained hyperthyroid (i.e. bellow 1.0) had little effect on REE. This might be because the body is maintaining thyroid status, or that REE is more like an on/off switch. However, this only covers relatively small changes in thyroxine dose.

It is unclear how supraphysiological doses effect REE. It seems likely that the ten times greater dose (500 mcg) used for depression would significantly increase REE.

This is consistent with the open label data. The dose is also similar. Combining this placebo-controlled trial with the three open-label supraphysiological thyroxine studies that I've seen, that is sufficient for me to conclude efficacy. Namely, combining with Pfeiffer et al (350 mcg), Rudas et al (235 mcg) and Bauer et al (482 mcg)

I would like to see if this study mentions nonresponders. Those three other studies found roughly a 50% response rate. Thus, the effect size in responders may be twice as significant.

Thus, a 15% expected increase would be reasonable for a euthyroid subject such as myself. However, since T3 reduces weight compared to T4, it is possible the weight loss indicates greater energy expenditure.

Interesting that the diet group worked better. I'd like to see if it's statistically significantly better than the drug group. It's also worth asking whether sodium was the only important dietary change, or if avoiding sodium caused many other dietary improvements.

Fascinating. Neck circumference suggests that sodium intake may indeed be the significant dietary factor. The recommended diet wasn't even very restricted in sodium.

Is there anything it can't do? I have noted, however, that larger doses cause nausea for me. That is, 3 or more grams on an empty stomach. I just vomited after taking 7.5 grams before my meal, but I have not yet established the causal link. It is the largest amount I've ever taken at one time. I suspect that it may have contributed significantly, but that it was also one out of half a dozen factors.